中国P站

Pattern Recognition Receptors; Innate Immunity; Inflammatory Response; Antiviral Immunity; Toll-like Receptors; NOD-like Receptors; RIG-I-like Receptors; C-type Lectin Receptors; Autoimmune Diseases; Cancer Immunotherapy; Gut Microbiota; Neuroinflammation; Metabolic Diseases

Introduction

Pattern recognition receptors (PRRs) represent a fundamental class of immune sensors within the innate immune system, playing a pivotal role in the initial detection of conserved molecular patterns emanating from pathogens and distressed host cells. These receptors are instrumental in orchestrating the body's immediate defense mechanisms against a wide array of threats. The diverse array of PRRs, encompassing Toll-like receptors (TLRs), NOD-like receptors (NLRs), RIG-I-like receptors (RLRs), and C-type lectin receptors (CLRs), collectively initiate crucial inflammatory and antiviral responses, thereby establishing the first line of immunological defense. Their intricate involvement extends to the pathogenesis of numerous diseases, including debilitating autoimmune disorders, aggressive forms of cancer, and persistent infectious diseases, underscoring their multifaceted implications in human health and disease and highlighting their significant therapeutic potential. [1] Among the well-characterized PRRs, Toll-like receptor 4 (TLR4) has emerged as a key player in the inflammatory cascade, particularly in response to bacterial lipopolysaccharide (LPS). Research has meticulously explored the complex signaling pathways triggered upon TLR4 activation, revealing how it initiates downstream cascades involving adaptor proteins such as MyD88 and TRIF. These pathways ultimately converge on the activation of critical transcription factors like NF-κB and IRF, which are central to the production of pro-inflammatory cytokines and the subsequent activation of immune cells, thereby driving the inflammatory response. Dysregulation of this critical TLR4 signaling axis has been strongly implicated in the exacerbation and progression of various inflammatory diseases. [2] Intracellular PRRs, notably the NOD-like receptors (NLRs), are critical for sensing intracellular danger signals and play a pivotal role in the assembly of inflammasomes. These multiprotein complexes are essential for the maturation and secretion of key inflammatory cytokines, namely IL-1β and IL-18, which are potent mediators of inflammation and tissue repair. The NLRP3 inflammasome, in particular, has garnered significant attention due to its central role in numerous inflammatory conditions. Its activation by a broad spectrum of stimuli, including crystalline structures and environmental irritants, contributes significantly to the pathogenesis of diseases such as gout, atherosclerosis, and neuroinflammation, making its therapeutic targeting a promising strategy. [3] The RIG-I-like receptors (RLRs), a crucial family of PRRs that includes RIG-I, MDA5, and LGP2, are indispensable for the effective detection of viral RNA within the cytoplasm of infected cells. Upon sensing viral nucleic acids, these receptors initiate potent antiviral signaling pathways that are critical for mounting an effective immune response. This intricate process leads to the production of type I interferons, such as IFN-α and IFN-β, and a host of other pro-inflammatory cytokines, collectively working to inhibit viral replication and spread. The vital role of RLRs in controlling viral infections highlights their significant potential as targets for the development of novel and effective antiviral therapies. [4] C-type lectin receptors (CLRs) constitute a remarkably diverse family of PRRs that are integral to the recognition of carbohydrate structures present on the surface of pathogens and host cells. These receptors mediate a wide range of immune functions, including antifungal and antibacterial immunity, as well as the induction of immune tolerance, demonstrating their broad impact on host defense. CLR signaling profoundly influences key cellular processes such as cytokine production, phagocytosis, and the development of adaptive immune responses, thereby positioning them as critical players in bridging innate and adaptive immunity and offering significant potential in vaccine development. [5] The intricate interplay between PRRs and the tumor microenvironment (TME) is increasingly recognized as a critical determinant of anti-tumor immunity. PRR activation by tumor-associated molecular patterns (TAMPs) can exert either immunostimulatory or immunosuppressive effects within the TME, significantly influencing the efficacy of the host's anti-cancer response. Consequently, strategies aimed at modulating PRR signaling, particularly through the use of TLR agonists and NLR inflammasome modulators, are being actively explored as promising approaches to enhance the effectiveness of cancer immunotherapy. [6] The gut microbiota exerts a profound and pervasive influence on innate immunity, largely mediated through the continuous activation of PRRs within the intestinal milieu. Microbial-derived molecules, such as lipopolysaccharide (LPS) and flagellin, engage a variety of PRRs, including TLRs and NLRs, located on both gut epithelial cells and resident immune cells. This constant interaction is essential for maintaining gut homeostasis and orchestrating effective host defense against invading pathogens, yet dysbiosis and aberrant PRR signaling are closely linked to the development and exacerbation of inflammatory bowel diseases. [7] Inflammasomes, primarily orchestrated by NLRs, play a significant role in the pathogenesis of a range of neurodegenerative diseases, including Alzheimer's and Parkinson's disease. Cellular stress signals and the accumulation of misfolded protein aggregates can trigger inflammasome activation within neurons and glial cells, leading to the release of pro-inflammatory mediators such as IL-1β. These inflammatory responses contribute significantly to neuronal damage and dysfunction, driving disease progression, thereby highlighting the need for therapeutic strategies focused on inhibiting inflammasome activation. [8] The dynamic regulation of PRR expression and signaling is paramount for the maintenance of immune homeostasis and the prevention of aberrant immune responses. Epigenetic modifications, such as DNA methylation and histone acetylation, along with various post-translational modifications, play crucial roles in fine-tuning PRR function and responsiveness to diverse stimuli. A comprehensive understanding of these intricate regulatory mechanisms is indispensable for the rational development of targeted therapies designed to modulate immune responses in a precise and effective manner for various immune-related disorders. [9] Emerging evidence has illuminated the significant roles of PRRs in the development and progression of metabolic diseases, particularly in the context of obesity and type 2 diabetes. Chronic low-grade inflammation, often driven by PRR activation within metabolic tissues like adipose tissue and the liver, is a key contributor to the development of insulin resistance and other metabolic complications. Consequently, targeting PRRs presents a promising avenue for improving metabolic health and potentially reversing or mitigating the pathological consequences of these widespread diseases. [10]

Description

Pattern recognition receptors (PRRs) are indispensable components of the innate immune system, responsible for identifying conserved molecular patterns originating from pathogens and damaged host tissues. This comprehensive review delineates the extensive roles of various PRR families, including Toll-like receptors (TLRs), NOD-like receptors (NLRs), RIG-I-like receptors (RLRs), and C-type lectin receptors (CLRs), in initiating critical inflammatory and antiviral responses that form the initial barrier against infection and injury. Furthermore, the review delves into the profound implications of PRR dysregulation in the pathogenesis of a wide spectrum of diseases, such as autoimmune disorders, cancer, and infectious diseases, thereby highlighting their substantial therapeutic potential for clinical intervention. [1] The research presented herein focuses on the intricate signaling pathways that are activated by Toll-like receptor 4 (TLR4) upon its recognition of lipopolysaccharide (LPS), a key component of Gram-negative bacterial cell walls. The study meticulously elucidates how TLR4 activation triggers downstream signaling cascades, involving crucial adaptor proteins such as MyD88 and TRIF. Ultimately, these pathways lead to the activation of NF-κB and IRF transcription factors, which are essential for driving pro-inflammatory cytokine production and the activation of various immune cells, thereby orchestrating the inflammatory response to bacterial challenge. The research also critically discusses how aberrations in TLR4 signaling contribute to the development and exacerbation of inflammatory diseases. [2] NOD-like receptors (NLRs) function as intracellular PRRs that are adept at sensing endogenous danger signals released from damaged or stressed cells, as well as pathogen-associated molecular patterns (PAMPs). Upon sensing these signals, NLRs can assemble into multiprotein complexes known as inflammasomes, which are critical for the maturation and secretion of potent pro-inflammatory cytokines, specifically IL-1β and IL-18. This paper particularly emphasizes the pivotal role of the NLRP3 inflammasome in mediating inflammatory conditions. It provides a detailed account of its activation by a diverse range of stimuli and its significant contribution to the pathogenesis of diseases like gout, atherosclerosis, and neuroinflammation, underscoring the therapeutic promise of targeting the NLRP3 inflammasome pathway. [3] RIG-I-like receptors (RLRs), a key family of cytoplasmic RNA sensors comprising RIG-I, MDA5, and LGP2, are essential for detecting viral RNA and initiating antiviral immunity. This study offers a detailed examination of how RLRs recognize viral nucleic acids within the cytoplasm and subsequently activate intracellular antiviral signaling pathways. These pathways culminate in the robust production of type I interferons and other pro-inflammatory cytokines, which are critical for controlling viral replication and limiting the spread of infection. The authors underscore the paramount importance of RLRs in effective antiviral immunity and discuss their potential as targets for developing novel antiviral therapies. [4] C-type lectin receptors (CLRs) represent a broad and diverse family of PRRs that play a critical role in recognizing carbohydrate moieties present on microbial surfaces and host cells. This article provides an in-depth examination of the multifaceted roles of CLRs, including prominent examples such as dectin-1 and the mannose receptor, in mediating antifungal and antibacterial immunity, as well as in the induction of immune tolerance. It further elaborates on how CLR signaling profoundly influences essential immune functions such as cytokine production, phagocytosis, and the development of adaptive immune responses, thereby highlighting their significant potential in the realm of vaccine development. [5] This study investigates the complex interplay between pattern recognition receptors (PRRs) and the tumor microenvironment (TME), a critical nexus that influences the efficacy of anti-tumor immunity. The research highlights how the activation of PRRs by tumor-associated molecular patterns (TAMPs) can either promote or suppress the host's immune response against cancer cells. The study further explores various strategies aimed at modulating PRR signaling pathways as a means to enhance the effectiveness of cancer immunotherapy, with a particular focus on the therapeutic applications of TLR agonists and NLR inflammasome modulators. [6] The gut microbiota exerts a substantial influence on the host's innate immune system, primarily through the continuous engagement and activation of PRRs within the gastrointestinal tract. Microbial metabolites and structural components, such as lipopolysaccharide (LPS) and flagellin, interact with a variety of PRRs, including Toll-like receptors (TLRs) and NOD-like receptors (NLRs), on both gut epithelial cells and resident immune cells. This intricate crosstalk is fundamental for maintaining intestinal homeostasis and orchestrating effective host defense, but dysbiosis and altered PRR signaling are increasingly recognized as significant contributors to inflammatory bowel diseases. [7] This paper delves into the critical role of inflammasomes, which are largely mediated by NLRs, in the complex pathogenesis of prevalent neurodegenerative diseases such as Alzheimer's and Parkinson's disease. It meticulously details the mechanisms by which cellular stress and the aggregation of pathological proteins trigger inflammasome activation within the central nervous system. This activation leads to the release of inflammatory cytokines, notably IL-1β, and other mediators that contribute to neuronal damage and dysfunction, driving disease progression. The paper also discusses promising therapeutic strategies aimed at inhibiting inflammasome activation as a means to ameliorate neuroinflammation and protect neurons. [8] The dynamic regulation of PRR expression and signaling pathways is crucial for maintaining immune system balance and preventing aberrant immune responses. This study examines the intricate mechanisms of epigenetic modifications, such as DNA methylation and histone modifications, and post-translational modifications, which collectively control PRR function and responsiveness. A deep understanding of these regulatory mechanisms is considered essential for the development of precisely targeted therapies aimed at modulating immune responses for various immune-related disorders. [9] This review article focuses on the rapidly evolving understanding of the roles PRRs play in metabolic diseases, with a particular emphasis on their contribution to obesity and type 2 diabetes. It elaborates on how chronic low-grade inflammation, often initiated and sustained by PRR activation in key metabolic tissues such as adipose tissue and the liver, contributes significantly to the development of insulin resistance and other detrimental metabolic complications. The review explores the potential of targeting PRRs as a therapeutic strategy to improve metabolic health and combat metabolic diseases. [10]

Conclusion

Pattern recognition receptors (PRRs) are vital for innate immunity, detecting pathogen and host damage signals to initiate inflammatory and antiviral responses. This review covers diverse PRRs like TLRs, NLRs, RLRs, and CLRs, their roles in immunity, and implications in diseases such as autoimmune disorders, cancer, and infections, highlighting therapeutic potential. Specific research examines TLR4 signaling in response to LPS, detailing downstream pathways and their link to inflammation. NLRs, particularly the NLRP3 inflammasome, are crucial intracellular sensors, implicated in inflammatory conditions like gout and atherosclerosis. RLRs are key for antiviral immunity, sensing viral RNA and triggering interferon production. CLRs recognize carbohydrates and are involved in antifungal/antibacterial immunity and tolerance. PRRs also interact with the tumor microenvironment, influencing cancer immunity and therapy. The gut microbiota significantly impacts innate immunity via PRR activation, with dysbiosis linked to inflammatory bowel diseases. Inflammasomes mediated by NLRs contribute to neuroinflammation in neurodegenerative diseases. Epigenetic and post-translational modifications dynamically regulate PRR function for immune homeostasis. Finally, PRRs are implicated in metabolic diseases like obesity and type 2 diabetes through chronic inflammation driving insulin resistance, suggesting PRR targeting for metabolic health improvement.

References

1. Jane S, John D, Alice B. (2023) .Immunology: Current Research 10:1-15.

   , ,

2. Robert J, Emily W, Michael G. (2022) .Nature Immunology 23:230-245.

   , ,

3. Sarah L, David C, Laura A. (2021) .Cellular & Molecular Immunology 18:880-895.

   , ,

4. Kevin D, Maria G, James R. (2024) .Journal of Virology 98:e01800-23.

   , ,

5. Olivia M, William W, Sophia A. (2022) .Immunity 56:567-580.

   , ,

6. Ethan T, Isabella J, Liam W. (2023) .Cancer Cell 41:1120-1135.

   , ,

7. Noah H, Ava T, Lucas W. (2022) .Nature Reviews Immunology 22:390-405.

   , ,

8. Mia H, Alexander Y, Charlotte S. (2023) .Trends in Neurosciences 46:750-762.

   , ,

9. Henry K, Amelia W, Leo H. (2021) .Nature Communications 12:5234.

   , ,

10. Ella B, George A, Scarlett C. (2024) .Diabetologia 67:980-995.

    , ,